TRANSDERM SCOP Rx
Generic Name and Formulations:
Scopolamine 1.5mg (delivers approximately 1mg over 3 days); transdermal patch.
Novartis Consumer Health
Indications for TRANSDERM SCOP:
Prevention of motion sickness and post-op nausea and vomiting.
Apply to dry skin behind ear; do not cut patch. Motion sickness: 1 patch at least 4 hours before travel; remove after 72 hours. Post-op: 1 patch evening before surgery; for cesarean section: 1 patch 1 hour before surgery. Remove 24 hours after surgery.
Narrow angle glaucoma. Allergy to belladonna alkaloids.
Wash hands and skin after use; avoid eyes. GI or urinary tract obstruction. Hepatic, renal, or metabolic dysfunction. Seizure. Psychosis. Elderly. Pregnancy (Cat.C). Nursing mothers.
Alcohol, other CNS depressants potentiate CNS depression. Additive anticholinergic effects with other anticholinergics, antihistamines (e.g., meclizine), antidepressants. May affect absorption of other drugs.
Dry mouth, drowsiness, blurred vision, disorientation, confusion, difficult urination; withdrawal symptoms may occur if used for >3 days.
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds